Bicycle therapeutics announces data updates across zelenectide pevedotin program and development strategy leveraging nectin4 gene amplification

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced the presentation of data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in breast cancer patients with nectin4 gene amplification at the 2024 san antonio breast conference symposium (sabcs) in san antonio, texas. the.
BCYC Ratings Summary
BCYC Quant Ranking